Clinical Trials on Multiple Trauma

Total 16400 results

Nantes University Hospital

Completed

Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

France
Biogen

Terminated

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting | Relapsing-Remitting Multiple Sclerosis

Canada
Biogen

Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Japan
University of Missouri, Kansas City

Completed

Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS (MIMS)

Relapsing-remitting Multiple Sclerosis

United States
University of Missouri, Kansas City
National Multiple Sclerosis Society

Completed

Development of a Motivational Intervention to Improve Treatment Adherence in MS (MIMS)

Relapsing-remitting Multiple Sclerosis

United States
Biogen

Withdrawn

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate (TECNERGY)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (REFINE)

Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Germany, Belgium
Biogen

Completed

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE)

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Czech Republic, France, Italy, Mexico, South Africa, United Kingdom, Germany, Poland, Romania, Ukraine, Netherlands, Austria, Canada, Israel, New Zealand, Slovakia, Greece, Serbia, India, Belgium, Switzerland, ... and more
Waukesha Memorial Hospital
The Cleveland Clinic

Completed

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Russian Federation
Merck KGaA, Darmstadt, Germany

Completed

A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) (TOURIMS)

Relapsing-Remitting Multiple Sclerosis
Opexa Therapeutics, Inc.

Completed

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (TERMS)

Relapsing-Remitting Multiple Sclerosis

United States
Neurognostics

Terminated

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

United States
Pakistan Institute of Living and Learning
University of Manchester

Recruiting

Eye Movement Desensitization and Reprocessing (EMDR) for Police Personnel

Stress | Suicidal Ideation | Psychological Trauma

Pakistan
Fondation Lenval

Active, not recruiting

Pedopsychiatric and Multidisciplinary Research Devoted to Children Exposed to the Attack in Nice on July 14, 2016 (Program14-7)

Psychiatric Disorder | Trauma, Psychological

France
Peter Siesjö
University of Stellenbosch

Completed

Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury (SASAT)

Brain Trauma

South Africa
Sanofi

Recruiting

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Relapsing Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple Sclerosis

China, Turkey, Korea, Republic of, United States, Ukraine
University Hospital, Antwerp
Hasselt University; University Hospital, Ghent; AZ Sint-Jan AV; National MS Center... and other collaborators

Recruiting

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary-progressive Multiple Sclerosis

Belgium
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic

Completed

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Instituto Universitario de Oftalmobiología Aplicada...
Hospital del Río Hortega; Fundación Eugenio Rodríguez Pascual

Enrolling by invitation

Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis

Progressive Multiple Sclerosis | Multiple Sclerosis | Clinically Isolated Syndrome | Relapsing Remitting Multiple Sclerosis

Spain
University of Michigan
LFR International

Recruiting

Deploying Emergency Bystander Internet Training (DEBIT)

Trauma | Trauma Injury

Kenya, Nigeria, Sierra Leone, Uganda
Methodist Health System
University of Texas at Austin

Withdrawn

Commonly Used Drug Regimens for Rapid Sequence Intubation (RSI) of Trauma Patients in the Emergency Department

Trauma Patients

United States
Biogen

Completed

Clinical Disease Activity With Long Term Natalizumab Treatment

Relapsing-Remitting Multiple Sclerosis

Czechia, Belgium
Institute for Clinical Research

Unknown

Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS

Relapsing-Remitting Multiple Sclerosis

United States
Universidad Complutense de Madrid

Enrolling by invitation

A Comprehensive Third-generation Intervention for People With Psychosis and Post-traumatic Stress Symptoms (IITG-PPT)

Psychosis | Trauma, Psychological

Spain
Johns Hopkins Bloomberg School of Public Health
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Improving Mental Health and School Performance in Urban Eighth Graders

Depressive Symptoms | Trauma, Psychological | Disruptive Behavior

United States
Federal University of São Paulo

Unknown

Influence of Physical Exercise on Cognitive Functioning of Traumatic Brain Injury Patients

Brain Diseases | Central Nervous System Diseases | Brain Injuries | Craniocerebral Trauma | Trauma, Nervous System

Brazil
Brock University

Completed

A Pilot Nutrition Program for Spinal Cord Injury and MS

Multiple Sclerosis | Spinal Cord Injuries

Canada
AB Science

Completed

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Relapse Free

Poland, Spain, Bulgaria, France, Germany, Greece, Romania
University of Washington
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Bristol-Myers Squibb

Completed

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Multiple Indications Cancer

France, Poland
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

Malignancies Multiple

United States
Natalie Kreitzer
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

Caregiver Wellness After Traumatic Brain Injury (CG-WELL): An Intervention Designed to Promote Well-being in Caregivers of Acute Moderate to Severe Traumatic Brain Injuries (CG-Well)

Trauma, Brain

United States
Institut d'Anesthesiologie des Alpes Maritimes
Institut National de la Santé Et de la Recherche Médicale, France; PT Kalbe...

Terminated

Sodium-Lactate and Traumatic Brain Injury

Intracranial Hypertension | Severe Trauma Brain Injury

France
University of Monastir

Completed

The Value of the Canadian CT Head Rule and the New Orleans Criteria in Minor Head Trauma

Minor Head Injury

Tunisia
Bristol-Myers Squibb

Recruiting

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (AppreZiate)

Relapsing-remitting Multiple Sclerosis (RRMS)

Spain
Hoffmann-La Roche
PPD

Recruiting

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

Relapsing-Remitting Multiple Sclerosis

United States, Belgium, Canada, Spain, India, Italy, Mexico, Portugal, Argentina, Austria, Brazil, United Kingdom, Germany, Netherlands, Serbia, Australia, Bulgaria, France, Greece, Hungary, Poland, Ukraine, Estonia, Denmark, Croatia, Latvia and more
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Polpharma Biologics S.A.

Completed

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® (Antelope)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Belarus, Ukraine, Georgia, Croatia, Moldova, Republic of, Poland, Serbia
Cinnagen

Completed

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Iran, Islamic Republic of
Weill Medical College of Cornell University
Genzyme, a Sanofi Company

Completed

Measuring Active Microglia in Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Relapsing-Remitting Multiple Sclerosis

United States

Clinical Trials on Multiple Trauma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations